Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
That long post was almost a " I'm not a de-ramper but " style of rant.
Foralumab - the only fully human anti-CD3 specific mAb in clinical development.
Feature not benefit. Unproven therefore more investor risk than exiting options.
-Broad potential for a range of inflammatory and autoimmune diseases, nasal and oral administration....a game changer as IV is the goto route.... Which is more toxic for the user and more expensive for the hospital.
IV the route to go cause it has been proven to work. Nasal unnproven. Might work, might not.
-mAb market worth $130 billion by 2025.
Might has well sell hot dogs and quote value of the food market
-The company is also accelerating the development of TZLS-501, a fully human anti-IL6R mAb, towards the clinic for COVID-19 treatment. The innovative delivery route via handheld nebulizer or inhaler to the lung, directly targets the main site of inflammation.... Which thus far we know has been a success.. And TOPLINE date is due imminelty.....
Unproven
Suggest enroll in a couple of courses including evidence based medicine and risk : reward analysis.
I'm invested in TILS but your continual overstatement of ramp is just boring and suggests you think people are idiots. Do usva favour and shut up for a few days.
Foralumab - the only fully human anti-CD3 specific mAb in clinical development.
-Broad potential for a range of inflammatory and autoimmune diseases, nasal and oral administration....a game changer as IV is the goto route.... Which is more toxic for the user and more expensive for the hospital.
-mAb market worth $130 billion by 2025.
-The company is also accelerating the development of TZLS-501, a fully human anti-IL6R mAb, towards the clinic for COVID-19 treatment. The innovative delivery route via handheld nebulizer or inhaler to the lung, directly targets the main site of inflammation.... Which thus far we know has been a success.. And TOPLINE date is due imminelty.....
-All technologies patented!
-Tiziana’s Phase I clinical study of oral Foralumab in Crohn’s Disease showed its proprietary oral formulation of Foralumab to be well tolerated. Phase II trials are planned in H2 20. Its alternative formulation and safety profile could provide a very attractive alternative to IV drugs which include the blockbuster Humira which registered c $4bn in Crohn’s in 2018. Tiziana recently received the first-ever patent on oral delivery of all anti-CD3 monoclonal antibodies for the treatment of human disease supporting the differentiated approach
-Nasal Treatment with Foralumab for secondary progressive MS was well-tolerated in a Phase I trial and induced positive trends in biomarkers of immunomodulation and anti-inflammation in healthy volunteers. Data from these two Phase I trials with alternative oral and nasal routes of administration indicated that the toxicities that are commonly observed with anti-CD3 IV treatment were not observed.
-Fully Funded till 2022... Now also have 100 million if Need be.... Options price 150p minimum.
-New chief medical officer from REGENERON! - From 2010 to 2020, Dr Graham was VP of Strategic Program Direction, Immunology and Inflammation at Regeneron Pharmaceuticals, Inc., where he managed and oversaw a large portion of the Regeneron pipeline portfolio including leading the immunology and inflammation antibody products across all stages of development from preclinical to post-launch
-Main market move making TILS more attractive to large institutions.
-Once the results are shown this stock has the potential to go from 155p to £10 very easily.
-Current valuations £700 million... Excluding covid treatment and StemprintER..... Which without any results the current SP should be 400p..... Currently 155p...... Undervalued..... Matter of time until large Personal investors or funds purchase into this biotech stock.
Largest investors....Morgan Stanley now owns 350,005 shares of the company’s stock worth $1,165,000 after acquiring an additional 337,508 shares in the last quarter.